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Activation of the T cell receptor (TCR) by antigen is
the key step in adaptive immunity. In the abTCR,
antigen induces a conformational change at the
CD3 subunits (CD3 CC) that is absolutely required
for abTCR activation. Here, we demonstrate that
the CD3 CC is not induced by antigen stimulation of
the mouse G8 or the human Vg9Vd2 gdTCR. We
find that there is a fundamental difference between
the activation mechanisms of the abTCR and gdTCR
that map to the constant regions of the TCRab/gd
heterodimers. Enforced induction of CD3 CC with a
less commonly usedmonoclonal anti-CD3 promoted
proximal gdTCR signaling but inhibited cytokine
secretion. Utilizing this knowledge, we could dramat-
ically improve in vitro tumor cell lysis by activated
human gd T cells. Thus, manipulation of the CD3
CC might be exploited to improve clinical gd T cell-
based immunotherapies.INTRODUCTION
ab T cells use their ab T cell antigen receptor (abTCR) to recog-
nize an almost infinite number of peptide antigens presented
by major histocompatibility complex molecules (pMHC) on anti-
gen-presenting cells (APCs). In contrast, gd T cells have a rather
limited germline-encoded receptor repertoire. Their gdTCRs in
part recognize stress-induced self-antigens, lipids, or pyrophos-
phates that are secreted by somemicrobes or are overproduced
in tumor cells (Bonneville et al., 2010; Chien and Konigshofer,1704 Cell Reports 7, 1704–1715, June 12, 2014 ª2014 The Authors2007; Vantourout and Hayday, 2013). gdTCRs can also deliver
ligand-independent signals for gd T cell development in the
thymus (Jensen et al., 2008).
In mice, 1% of the gd T cells recognize the nonclassical
MHC class I molecule T22, which is expressed on activated
cells, such as lipopolysaccharide (LPS)-stimulated B cells
(Crowley et al., 2000; Matis et al., 1987). One example is the
G8 gdTCR that uses its CDR3d loop to bind with high affinity to
T22 (Adams et al., 2005; Crowley et al., 2000; Weintraub et al.,
1994).
In human blood, the main subset of gd T cells is Vg9Vd2 that
accounts for 2%–10% of all T cells. The Vg9Vd2 TCR recognizes
self and foreign nonpeptidic phosphorylated small organic
compounds, collectively termed phosphoantigens (Bukowski
et al., 1995, 1998; Constant et al., 1994; Espinosa et al., 2001;
Tanaka et al., 1995). Vg9Vd2 T cells are also stimulated by tumor
cells, such as the Daudi B cell lymphoma (Fisch et al., 1997), that
likely express high levels of phosphoantigens (Gober et al.,
2003). Antigen recognition and tumor cell killing by Vg9Vd2
T cells can be enhanced with aminobisphosphonates, such as
zoledronate (Roelofs et al., 2009), which increase accumulation
of endogenous phosphoantigen.
TCRs consist of a clonotypic TCRab or TCRgd heterodimer,
two CD3 dimers (CD3dε, CD3gε), and a zz dimer. TCRab and
TCRgd chains contain variable (V) immunoglobulin domains
that bind to the antigen, and constant (C) domains that associate
with CD3. CD3 and z contain tyrosines in their cytoplasmic tails
that are phosphorylated upon antigen binding to TCRab or
TCRgd. In this report, ‘‘TCRab’’ or ‘‘TCRgd’’ denote the TCRab
or TCRgd heterodimers, and ‘‘abTCR’’ or ‘‘gdTCR’’ the complete
TCRs including the CD3 and z chains. Although similar in domain
structure, the architecture of gdTCRs differs from that of abTCRs
(see the Discussion).
Figure 1. CD3 Conformational Change
Induction at Murine gdTCRs
(A) Schematic of the SH3-PD assay.
(B) The murine gd T cell hybridoma F30L31 and ab
T cell hybridoma 2B4 were left untreated () and
stimulated for 5 min at 37C or 0C with 5 mg/ml
anti-CD3 mAb 2C11 or for 5 min with pervanadate
(PV). After lysis, one aliquot of lysates was incu-
bated with SH3 beads and another with protein A-
and protein G beads. Lysates and bead-purified
proteins were analyzed by anti-z WB (n > 3).
(C) Pooled thymocytes and splenocytes of
TCRb/Vg1.1tg mice were stimulated at 37C
with anti-CD3 (2C11), anti-Vg1.1, or anti-TCRb
(H57-597) antibodies. The samples were treated
as in (B) (n = 3).
(D) F30L31 and 2B4 cells were left untreated () or
stimulated with 2C11 in the presence of 4 mM
EGTA. Additionally, cells were left untreated and
stimulated with 2C11, with 2C11 plus 1 mg/ml
ionomycin or with ionomycin alone in the presence
of 0.9 mM Ca2+. After lysis, one aliquot of lysates
was incubated with SH3 beads and another with
protein A and protein G beads. In the lysis and
washing buffers, EGTA or Ca2+ were present as
indicated. Lysates and bead-purified proteins
were analyzed by anti-z WB (n = 3).Stimulation of the abTCR and the gdTCR initiates intracellular
signaling cascades, such as Ca2+ influx, PI3K/AKT, Ras/Erk, and
NFkB pathways that are extensively studied. However, how
antigen binding to TCRab or TCRgd is communicated to the
cytosolic tails of CD3 and z is less well understood (Kuhns and
Davis, 2012). It has been suggested that the abTCR exists in
two conformations. In the closed conformation, adopted by the
unstimulated abTCR, the cytosolic tails of CD3 and z might be
shielded from phosphorylation (Minguet and Schamel, 2008).
In the open conformation, induced by productive antigen or anti-
body binding, CD3 and z phosphorylation might be promoted by
an unknown mechanism.
The experimental assay to measure this CD3 conformational
change (CD3 CC) makes use of the increased accessibility of a
proline-rich sequence (PRS) in the CD3ε cytoplasmic tail. In the
closed conformation, the PRS cannot bind to the first SH3
domain of the adaptor protein Nck. In contrast, in the open
conformation the PRS is accessible and thus binds to this SH3
domain (Borroto et al., 2013, 2014; de la Cruz et al., 2011; Gil
et al., 2002, 2005; Martı´nez-Martı´n et al., 2009; Minguet et al.,
2007). In fact, PRS exposure is correlated with an overall rear-
rangement in the structure of the CD3 and z cytoplasmic tails
(Risuen˜o et al., 2008).
The CD3 CC, as measured by PRS exposure, precedes CD3
phosphorylation (Gil et al., 2002) and is required for ab T cell
activation (Minguet et al., 2007), in that engineered ligands that
could not induce the CD3 CC did not result in abTCR phosphor-
ylation and downstream signaling. Likewise, point mutations in
the extracellular part of CD3ε that do not allow the outside-in
transmission of the CD3 CC, such as CD3εK76T or CD3εC80G,
inhibit abTCR signaling in vitro and in vivo (Martı´nez-Martı´n et al.,
2009). Thus, without theCD3CC, an abTCR cannot be activated.
CD3ε also contains a cytosolic basic-rich sequence that has
been proposed to interact with the acidic lipids of the innermem-Cbrane leaflet, shielding the cytoplasmic CD3ε tyrosines from
phosphorylation in the unstimulated abTCR (Deford-Watts
et al., 2009; Xu et al., 2008). Signaling by the abTCR leads to
Ca2+-influx neutralizing the negative lipid head groups and
thus, freeing the CD3ε cytosolic domain from the membrane
and promoting sustained signaling after the initial abTCR trigger
(Shi et al., 2013). Whether Ca2+ ions can influence the exposure
of the PRS is currently unknown.
To date, studies exploring the induction of the CD3 CC in
gdTCRs are lacking. Here, we tested if the CD3 CC can be
induced in the mouse and human gdTCR and whether it regu-
lates gd T cell activation.
RESULTS
Murine gdTCRs Undergo a Conformational Change at
CD3ε upon Antibody Stimulation
To assess whether the gdTCR undergoes the CD3 CC upon
stimulation, we used the murine gd T cell line F30L31 expressing
a Vg1.1 TCR, and as a control the mouse ab T cell line 2B4. We
carried out an SH3 pull-down (PD) assay using the first SH3
domain of Nck (Figure 1A). Anti-z western blotting showed that
resting, unstimulated TCRs did not bind to the SH3-coupled
beads (Figure 1B, lanes 1 and 4), whereas stimulation with the
anti-CD3 monoclonal antibody (mAb) 145-2C11 (2C11) at 37C
induced binding of the gdTCR and the abTCR to SH3 beads
(lanes 2 and 5). Stimulation with the phosphatase inhibitor perva-
nadate (PV) did not trigger binding of the TCRs to SH3 (lanes 3
and 6). As a further control, we incubated the lysates with protein
A- and G-coupled beads to immune-precipitate the TCRs via the
bound anti-CD3 mAb (lower panels). In addition, anti-TCRgd
antibody stimulation also induced gdTCR binding to SH3
(Figure S1A). A hallmark of the CD3 CC is its independence
from any metabolic process (Gil et al., 2002; Minguet et al.,ell Reports 7, 1704–1715, June 12, 2014 ª2014 The Authors 1705
Figure 2. The Murine G8 gdTCR Does Not Undergo the CD3 CC upon Antigenic Stimulation
(A) G8 gd hybridoma cells were stimulated at 37C with 5 mg/ml T22 monomer (T22m), tetramer (T22t) or anti-CD3 (2C11), and the SH3-PD was performed. The
ratio of SH3-bound TCR to total TCR (anti-CD3 IP) was calculated using the Odyssey infrared imager. The mean ± SD is shown (n = 3). Significances were
determined by the Student’s t test to compare unstimulated versus T22t stimulated samples; *p < 0.05.
(B) T1.4 ab hybridoma cells were incubated with 500 nM H2-Kd-pepABA monomer or 5 nM H2-Kd-pepABA tetramer, or 5 mg/ml 2C11, and the SH3-PD was
performed (n > 3).
(C) Schematic picture of the murine WT and chimeric TCRs. The domains of the G8 gdTCR are depicted in dark gray, including the T22-binding CDR3d loop
derived from the G8 gdTCR; the domains of the abTCR are in light gray.
(D) The 58ab transductants as indicated were stimulated with 5 mg/ml T22 tetramers, H2-Kd-pepABA (pMHC) tetramers or anti-CD3 (2C11), and the SH3-PD
was performed (n = 2).
(E) Using the 58.CDR3dVCab cells, the statistics from six experiments as in (D) was performed as in (A) normalizing to the unstimulated samples; **p < 0.01.
(F) The 58ab transductants were stimulated in triplicates for 2 hr as in (D). Subsequently, cells were stained with anti-CD3ε (2C11) mAb for flow cytometry (four
measurements are pooled). The mean ± SEM is shown. Significances between unstimulated and tetramer-stimulated cells were determined by the Student’s
t test; *p < 0.05; **p < 0.01.2007); thus, it even took place at 0C (Figure 1B, lanes 8 and 10).
This indicates that the induced binding of the gdTCR to SH3
reflects structural changes in CD3ε (the CD3 CC), as previously
described for the abTCR.
In primary ex vivo gd T cells from TCRb/Vg1.1tg mice, both
anti-CD3 and anti-Vg1.1, but not anti-TCRb mAbs, induced
binding of the gdTCR to the SH3 beads (Figure 1C). Thus, mouse
gdTCRs undergo conformational changes at CD3 upon stimula-
tion with gdTCR- and CD3-specific antibodies.
Next, we tested whether the TCR-mediated Ca2+ influx, which
was proposed to expose the cytosolic tail of CD3 in case of the
abTCR (Shi et al., 2013), was involved in the induction of the CD3
CC, as measured by the SH3-PD assay (Figure 1D). To this end,
we left F30L31 gd and 2B4 ab T cells unstimulated () or stimu-
lated them with anti-CD3 (2C11) in the absence of Ca2+ ions in
the medium, lysis, and washing buffers (all containing EGTA).
Alternatively, the stimulation was performed in the presence of
Ca2+ in these buffers and an optional treatment of the cells
with ionomycin to allow Ca2+ to flux into the cytosol. The pres-
ence or absence of Ca2+ did not influence the amount of TCRs
bound to the SH3-coupled beads, neither basally nor upon anti-
body stimulation (Figure 1D). Thus, Ca2+-induced structural
changes in the TCR are not related to the CD3 CC, and the
CD3 CC most likely is upstream of TCR-induced Ca2+ influx.1706 Cell Reports 7, 1704–1715, June 12, 2014 ª2014 The AuthorsAntigen Binding to Mouse G8 gdTCRs Does Not Trigger
the CD3 CC
Next, we tested whether natural antigens induce the structural
rearrangement of CD3ε in the gdTCR. For this purpose, we
made use of a murine hybridoma cell line expressing the G8
gdTCR (Bluestone et al., 1988) specific for the MHC I-like mole-
cule T22 (Schild et al., 1994). Upon stimulation of the G8 gd
hybridoma with biotinylated T22 monomers or tetramers for
5 min at 37C, the CD3 CC was not induced (Figure 2A, lanes
2 and 3). Surprisingly, tetramer binding to the G8 gdTCR signifi-
cantly reduced the CD3 CC, as compared to the basal level (Fig-
ures 2A, right panel, and S1B). As a control, we used anti-CD3
stimulation to trigger the CD3 CC. In contrast to the gdTCR,
MHC class I H2-Kd-pepABA (pMHC) tetramers induced the
CD3 CC in the mouse T1.4 ab hybridoma (Figure 2B), as pre-
viously described (Minguet et al., 2007). The G8 gd hybridoma
cells bound similar amounts of antigen tetramers as the T1.4
ab hybridoma cells (Figure S1C); thus, low levels of T22 tetramer
binding were not responsible for the lack of CD3 CC detection in
the gdTCR.
Next we used LPS-activated splenic B cells expressing
endogenous T22 as antigen-presenting cells (APCs) (Spaner
et al., 1995). Again, stimulation of the G8 gd hybridoma tended
to reduce the CD3 CC (Figure S1D). Thus, using the
best-characterized antigen for a specific gdTCR, our results
showed that a natural antigen did not induce the CD3 CC and
even evoked a slight reduction in the amount of conformationally
changed TCRs upon stimulation.
TheCapacity to Undergo the CD3CCMaps to the TCRab
Constant Regions
To test whether the gd cellular environment inhibited CD3 CC
induction, we expressed the G8 gdTCR in the murine ab hybrid-
oma 58ab defective for TCRa and TCRb expression, yielding
58.VgdCgd cells (Figure 2C, left panel, and S2). Stimulation
with T22 tetramers did not induce the CD3 CC (Figure 2D, lanes
1–3), indicating that the T22-G8 gdTCR system intrinsically lacks
the ability to undergo the CD3 CC.
Hence, our findings raised the question whether, in contrast to
conventional pMHC tetramers, the T22 antigen is in principle
incapable of inducing the CD3 CC, or whether it is intrinsic to
the G8 gdTCR that productive antigen engagement does not
result in the CD3 CC. To test these opposing possibilities, we
generated chimeric gd-ab TCRs and expressed them in
58ab cells (Figures 2C and S2). 58.VabCab cells express the
T1 abTCR, 58.VabCgd cells a chimeric TCR with the V regions
from T1 TCRab and the C regions from G8 TCRgd, and
58.CDR3dVCab cells express the 172 abTCR with the T22-bind-
ing CDR3d region of the G8 TCRd chains as reported (Adams
et al., 2008).
Strikingly, pMHC-tetramer stimulation of the chimeric VabCgd
TCR did not induce the CD3 CC, but rather reduced the
basal level (Figure 2D, lanes 7–9). In contrast, in the CDR3dVCab
the T22 tetramers induced the CD3 CC (Figure 2D, lanes 10–12)
that was statistically significant compared to unstimulated
cells (Figure 2E). Thus, neither the different binding geometry
nor the different affinity of the T22-gdTCR compared to the
pMHC-abTCR interaction determined CD3 CC induction. Rather
the G8 gdTCR is intrinsically different from the abTCR, because
the constant regions of the TCRgd chains do not transmit the
conformational change to CD3 upon antigen binding.
Ligand-induced TCR activation leads to intracellular
signaling, causing TCR internalization. Our wild-type (WT) and
chimeric TCRs were internalized upon stimulation with their
corresponding T22 or pMHC tetramers, indicating that induc-
tion of the CD3 CC was not required for gdTCR activation
(Figure 2F).
Triggering of the CD3 Conformational Change in the
Human Vg9Vd2 TCR
Next, we tested whether the CD3 CC can be induced in a human
Vg9Vd2 gd T cell clone (Fisch et al., 1990b; Fisch et al., 1997).
Stimulation with the anti-CD3 mAb UCHT1 triggered the CD3
CC (Figure 3A, lanes 2 and 8). However, the more commonly
used anti-CD3 mAb OKT3 showed markedly reduced potency
in the induction of the CD3 CC at 37C and was completely
inactive at 0C (lanes 3 and 9). However, similar amounts of
TCR were bound by UCHT1 and OKT3, because protein A-
and G-coupled beads precipitated similar amounts of anti-
body-bound TCRs (z chain detection, lower panels). As
expected, anti-TCRgd but not pervanadate (PV) stimulation
induced the CD3 CC (lanes 6 and 4). The same result was ob-Ctained with a different Vg9Vd2 T cell clone (data not shown).
Similarly, when using human freshly isolated, purified gd
T cells, OKT3 was a less potent inducer of the CD3 CC as
compared to UCHT1 or anti-TCRgd (Figure 3B).
In contrast, UCHT1 and OKT3 equally induced the CD3 CC
in human Jurkat ab T cells (Figure 3C, lanes 2 and 3). The
lack of structural changes at CD3 in the gdTCR upon OKT3
stimulation could be due to the gdTCR itself or differing cellular
environments in gd compared to ab T cells. To distinguish
between these possibilities, we used a TCRb-deficient Jurkat
cell line expressing the human Vg9Vd2 TCR (Jk.Vg9Vd2) (Alibaud
et al., 2001). Again, UCHT1 was much more potent than OKT3
in triggering the CD3 CC (Figures 3C, lanes 5 and 6, S3A,
and S3B). In conclusion, UCHT1 was a much more potent
trigger for the CD3 CC in the human Vg9Vd2 TCR than OKT3,
and differential induction of the CD3 CC in the human gdTCR
compared to the human abTCR is due to intrinsic properties of
these TCRs.
The human Vg9Vd2 TCR is naturally stimulated by phospho-
antigens (Bukowski et al., 1995; Constant et al., 1994). We
stimulated the Vg9Vd2 T cell clone with the two most commonly
used synthetic phosphoantigens bromohydrin pyrophosphate
(BrHPP) or isopentenyl pyrophosphate (IPP) (Espinosa et al.,
2001) and could not detect the CD3 CC above background
(Figure 3D, lanes 2 and 3). As a positive control, UCHT1 triggered
the CD3 CC (lane 4). Furthermore, stimulation with Daudi cells
(Fisch et al., 1997) or zoledronate (ZOL)-pulsed Daudi cells
with increased levels of endogenous phosphoantigens (Roelofs
et al., 2009) did not induce the CD3 CC (Figures 3E, lanes 2
and 3, and S3C).
Next, we quantified tumor necrosis factor (TNF)-a production
using the same concentration of the stimuli as for the CD3 CC
assay (Figure 3F). UCHT1 induced TNF-a production to an extent
similar that obtained via stimulation by Daudi or Daudi+ZOL,
and 4-fold less compared to IPP. Hence, induction of the CD3
CC did not correlate with TNF-a production, indicating that
CD3 CC induction is not required for TNF-a production by gd
T cells. As a control, stimulation with Daudi cells neither induced
the CD3 CC in the Vg9Vd2 clone nor activated an ab T cell clone
(Figures 3E and 3F).
In conclusion, using phosphoantigens as well as antigen-
expressing Daudi cells, we did not detect the CD3 CC in human
Vg9Vd2 TCRs. This is in strong contrast to the abTCR where
stimulation with pMHC tetramers and APCs induce this confor-
mational change (de la Cruz et al., 2011; Gil et al., 2005, 2008;
Minguet et al., 2007; Risuen˜o et al., 2005, 2006).
CD3 CC Induction at the gdTCR Correlates with
Activation of TCR-Proximal Signaling Events
To investigate the influence of the CD3 CC on gdTCR activation,
we compared the effects of UCHT1 and OKT3 on human gd
T cells using different functional readouts. To ensure that equal
numbers of gdTCRs were stimulated, we used both mAbs at
5 mg/ml—a concentration at which similar amounts of gdTCRs
were bound to UCHT1 and OKT3 (Figure 3A). Although UCHT1
stimulation evoked a strong Ca2+ influx, OKT3 led to a much
weaker response in the Vg9Vd2 T cell clone (Figure 4A) and in
freshly isolated, purified human gd T cells (Figure 4B). In abell Reports 7, 1704–1715, June 12, 2014 ª2014 The Authors 1707
Figure 3. CD3 CC Induction at the Human Vg9Vd2 TCR
(A) A human Vg9Vd2 T cell clone was left untreated or stimulated for 5 min at 37Cwith 5 mg/ml of the anti-CD3mAbs UCHT1 andOKT3, pervanadate (PV) or anti-
TCRgd (clone 5A6E9). Cells were also stimulated for 30 min at 0C. After lysis, the SH3-PD was performed (n > 3).
(B) Freshly isolated, purified human gd T cells (gdPBMCs) were stimulated for 5 min at 37C with 5 mg/ml UCHT1, OKT3, and anti-TCRgdmAbs, and the SH3-PD
was performed (n = 1).
(C) Jurkat and Jk.Vg9Vd2 cells were stimulated for 30 min at 0C with 5 mg/ml UCHT1 and OKT3, and the SH3-PD was performed (n > 3).
(D) BrHPP (500 nM) or IPP (30 mM) was added to the Vg9Vd2 clone. Cells were gently centrifuged and left at 37C for 60min or stimulated for 5min with UCHT1 as
above. Cells were mildly lysed using 0.3% Brij58. The SH3-PD was performed (n > 3).
(E) The human Vg9Vd2 and a human ab T cell clonewere left unstimulated and stimulated for 30min with Daudi cells, zoledronate (ZOL)-pulsed Daudi cells or as a
control, with 5 mg/ml UCHT1. The SH3-PD was performed (n > 3). The statistics were performed as in Figure 2A; n.s., not significant.
(F) The Vg9Vd2 (left) and ab (right) T cell clones were stimulated with Daudi, ZOL-pulsed Daudi cells, 30 mM IPP, or 5 mg/ml UCHT1 for 18 hr. TNF-a concentration
was measured by ELISA (n > 3). The mean ± SD is shown.Jurkat cells in which both UCHT1 andOKT3 induced the CD3CC
(Figure 3C), both antibodies triggered a strong Ca2+ influx
(Figure S4A).
Using a multiplexed bead assay, we assessed the phos-
phorylation kinetics of signaling proteins downstream of the
TCR, such as Akt, Erk, and IkBa. In the Vg9Vd2 T cell
clone, UCHT1 triggered a transient and strong phosphorylation
of all three proteins (Figure 4C). In sharp contrast, OKT3 stim-
ulation led to a slow and gradual increase in phosphorylation. A
similar result was obtained with human purified gd T cells
(Figure S4B). In addition, Vg9Vd2 TCR downmodulation
from the cell surface was slightly enhanced by UCHT1
compared to OKT3 (Figure S4C). We conclude that triggering
of the CD3 CC in the gdTCR led to enhanced proximal sig-
naling events, as compared to stimulation in the absence of
the CD3 CC.
Deglycosylation of the Vg9Vd2 TCR Facilitates CD3 CC
Induction and Ca2+ Influx
Because CD3 glycosylation differs between the gdTCR and
abTCR (Alarcon et al., 1987; Krangel et al., 1987; Siegers et al.,1708 Cell Reports 7, 1704–1715, June 12, 2014 ª2014 The Authors2007), we tested whether deglycosylation of the gdTCR
modifies the ability of OKT3 to trigger the CD3 CC. Treatment
of the Vg9Vd2 T cell clone with N-acetyl neuraminidase (NA), to
cleave sialic acid sugars, allowed CD3 CC induction by OKT3
(Figure 5A, lane 5). The gd-specific pattern of CD3 glycosylation
is dependent on the expression of the TCRgd chains and not
the cellular background (Siegers et al., 2007). In an ab cellular
background (Jk.Vg9Vd2 cells) OKT3 was also unable to
induce the CD3 CC in the gdTCR (Figure 3C). However, de-
glycosylation allowed the CD3 CC to take place (Figure S4D).
Deglycosylation also increased the CD3 CC induced by
UCHT1 (Figure 5A), indicating that this effect is not specific for
OKT3.
Next, we tested whether supplementing OKT3 stimulation
with the CD3 CC by deglycosylating the gd T cells influences
TCR-induced signaling. Although OKT3 stimulation alone did
not result in a measurable Ca2+ influx (Figure 5B), enhanced
Ca2+ influx was detected when the Vg9Vd2 T cell clone was de-
glycosylated prior to OKT3 stimulation (Figure 5B). Thus, the
specific glycosylation of the gdTCR controls inducibility of the
CD3 CC and its associated signal transduction.
Figure 4. UCHT1, but Not OKT3, Stimulation Promotes TCR-Prox-
imal Intracellular Signaling
(A) The human Vg9Vd2 T cell clone was loadedwith Indo-1 and stimulated with
5 mg/ml UCHT1 and OKT3. The Indo-1 ratio was integrated over 6 min and
measured by flow cytometry.
(B)Human freshly isolated,purifiedgdTcells (gdPBMCs)weremeasuredas in (A).
(C) The human Vg9Vd2 T cell clone was stimulated with 5 mg/ml UCHT1 and
OKT3 for 1, 3, 5, and 15 min. Phospho-Akt (solid line, y axis on left), phospho-
Erk (dashed line, y axis on right), and phospho-IkBa were measured by a
multiplexed-bead assay performed on cell lysates. All panels were performed
n > 3. The mean ± SD is shown.Multimerization of OKT3 Facilitates the CD3 CC,
Thereby Enhancing Ca2+ Influx
For the abTCR, antigen-TCR interactions of high valency favor
the induction of the CD3 CC (Minguet and Schamel, 2008). In
order to enable OKT3 to simultaneously bind to more than two
gdTCRs, we costimulated with an anti-k antibody that binds to
the k light chain of OKT3. Indeed, under these conditions the
CD3 CC in the gdTCR was induced (Figure 5C, lane 6). Interest-
ingly, anti-k had little or no effect on UCHT1 induction of the CD3
CC (lanes 2 and 5). Accordingly, anti-k treatment enabled OKT3-
triggered Ca2+ influx in gd T cells (Figure 5D, upper panel). As a
control, anti-k did not significantly enhance Ca2+ influx stimu-
lated by UCHT1 (lower panel). Likewise, OKT3 multimerizationCusing an anti-mouse immunoglobulin (Ig) G antibody led to
CD3 CC induction and Ca2+ influx (Figures S4D and S4E). These
experiments suggest that the differences in triggering signaling
downstream of the gdTCR by soluble UCHT1 or OKT3 are due
to their differential capacity to induce the CD3 CC.
gdTCRs Containing Mutant CD3 CC-Defective CD3ε
Chains Had Reduced Capability to Induce Ca2+ Influx
Next, we made use of two CD3ε mutants, K76T and C80G, that
weakly and a strongly inhibit induction of the CD3 CC (Figure 5E)
(Martı´nez-Martı´n et al., 2009). WT and mutant murine CD3ε
chains were expressed in the mouse gd F30L31 cells, yielding
F.εWT, F.εK76T, and F.εC80G cells. By using IRES-GFP con-
structs, those cells expressing the exogenous CD3ε can be iden-
tified. The GFP+ F.εWT, F.εK76T, and F.εC80G cells expressed
similar gdTCR levels on their surface (Figure S5A). When they
were stimulated with anti-CD3 mAb, a strong correlation be-
tween the capacity to induce the CD3 CC and the extent of
Ca2+ flux was observed (GFP+ gated cells, Figure 5F), again
showing that Ca2+ influx is promoted by the CD3 CC.
Induction of the CD3CCSuppresses CD69 Upregulation
and Cytokine Secretion by gd T Cells
Next, we testedwhether theCD3CC is required for the activation
of gdTCR-induced distal events such as upregulation of the
activation markers CD69 and CD25, cytokine secretion or prolif-
eration. To this end, we stimulated the murine F.εWT, F.εK76T,
and F.εC80G cells with anti-CD3; we found that CD69 and
CD25 were induced in both WT and CD3 CC mutant CD3ε-
expressing gd T cells (Figure 6A; data not shown). In fact, signif-
icantly more cells upregulated CD69 when the CD3 CC was
suppressed (Figure 6A).
To corroborate this finding in human cells, our Vg9Vd2 T cell
clone was stimulated using soluble OKT3 and UCHT1 mAbs.
Again, OKT3 led to a slightly better induction of CD69 and
CD25 on the cell surface (Figure 6B). In human freshly isolated,
purified gd T cells, CD69 and CD25 were upregulated to a similar
extent by both soluble UCHT1 and OKT3 (Figure 6C).
At the same time, we measured cytokines secreted into the
supernatant using a multiplexed bead assay. Surprisingly,
OKT3 induced a much greater release of interferon (IFN)-g and
TNF-a as compared to UCHT1 at all concentrations tested (Fig-
ures 6D and S5B). In contrast, when we stimulated the ab T cell
clone, which can undergo the CD3 CC induced by either UCHT1
or OKT3 stimulation, equal amounts of IFN-g and TNF-a were
secreted (Figure S5C). Next, we multimerized UCHT1 and
OKT3 by adhesion to a plastic dish, promoting conditions in
which OKT3 induces the CD3 CC. As expected, secretion of
IFN-g and TNF-awas similar in cells stimulated with plate-bound
OKT3 or UCHT1 (Figure 6E).
Similar to cytokine secretion, soluble OKT3 induced stronger
proliferation of short-term cultured human gd T cells than
UCHT1 (Figures 6F and S5D).
Induction of the CD3 CC Promotes gd T Cell-Mediated
Tumor Lysis
Because the CD3 CC differentially influences gd T cell activa-
tion, we asked whether Vg9Vd2 T cell effector functions, suchell Reports 7, 1704–1715, June 12, 2014 ª2014 The Authors 1709
Figure 5. Induction of theCD3CCPromotes
Strong and Early Ca2+ Influx
(A) The human Vg9Vd2 T cell clone was left
untreated or degylcosylated with N-acetyl neur-
aminidase (NA) for 1 hr at 37C. Subsequently,
cells were stimulated with 5 mg/ml UCHT1 or OKT3
for 5 min, and the SH3-PD was performed.
(B) The Vg9Vd2 T cell clone was left untreated or
deglycosylated as in (A) and Ca2+ influx was
measured upon OKT3 stimulation as before.
(C) Jk.Vg9Vd2 cells were stimulated with 5 mg/ml
UCHT1 or OKT3 with or without 2.5 mg/ml anti-k
antibodies at 37C, and the SH3-PD was per-
formed.
(D) For Ca2+ measurements using the Vg9Vd2
T cell clone 2.5 mg/ml anti-k was added simulta-
neously with 5 mg/ml UCHT1 or OKT3 as indicated.
(E) Extent of CD3CC induction in the CD3εK76T
and CD3εC80G mutants.
(F) F.εWT, F.εK76T, and F.εC80G cells were
stimulated with 10 mg/ml anti-mouse CD3 (2C11),
and Ca2+ influx was measured while gating on the
GFP+ cells. All panels were performed n = 3,
except (C) and (D), which were performed n = 2.as tumor cell lysis, can be modulated by altering the CD3 CC.
Stimulating gd T cell cultures from different healthy donors
with 0.5 or 5 mg/ml UCHT1 (which induces the CD3 CC)
dramatically enhanced target cell lysis of the pancreatic tumor
cell line Panc89 such that all tumor cells were lysed by 24 hr
(Figures 7A, 7B, and S6). In contrast, OKT3 (which hardly trig-
gers the CD3 CC) did not enhance tumor lysis. High concentra-
tions of anti-CD3 mAbs induced cell death in activated gd
T cells (Janssen et al., 1991; Kabelitz et al., 1994). Therefore,
we examined lower mAb concentrations as well as different
effector/target cell ratios. UCHT1, but not OKT3, augmented
tumor cell killing by the gd T cells also at 0.05 mg/ml (Figures
7B and S6A) and at different effector/target ratios using gd
T cell cultures from different donors (Figure S6A). The effect
of UCHT1 was dependent on gd T cells, because the growth
of Panc89 cells alone was neither affected by UCHT1 nor by
OKT3 (Figure 7C). In most cases OKT3 had a blocking effect
on tumor cell lysis (Figures 7A, 7B, and S6A), as demonstrated
previously (Fisch et al., 1990a). The differential activity of the
two antibodies was neither due to differences in the induction
of gd T cell apoptosis (Figure S6B) nor to antibody-dependent
cellular cytotoxicity, because most gd T cells in our cultures
(>97%) and Panc89 cells were negative for CD16 (data not
shown). In conclusion, induction of the CD3 CC by UCHT1
drastically enhanced the tumor-killing capacity of human gd
T cells.1710 Cell Reports 7, 1704–1715, June 12, 2014 ª2014 The AuthorsLast, we transduced our gd T cell
cultures with lentiviral vectors encoding
murine CD3εWT and CD3εK76T. Murine
CD3εC80G was not expressed well on
human T cells (not shown). In both
cultures, approximately 5% of the cells
expressed the murine CD3ε with a similar
MFI (64 for CD3εWT and 67 forCD3εK76T, not shown). Stimulation with the anti-mouse CD3
mAb 2C11, which is a strong inducer of the CD3 CC (Figures 1
and 2), enhanced tumor cell killing by cells expressing CD3εWT
more than those expressing CD3εK76T (Figure S6C). A similar
result was obtained in a second experiment (Figure S6D). These
experiments corroborate our finding that the CD3 CC promotes
gd T cell cytotoxicity.
DISCUSSION
Here we show that a hallmark of the mechanism behind abTCR
triggering does not hold true for the three gdTCRs tested. The
CD3 CC is required for abTCR activation (Martı´nez-Martı´n
et al., 2009; Minguet et al., 2007) and thus is induced by all
agonistic pMHCs tested (de la Cruz et al., 2011; Gil et al.,
2005, 2008; Minguet et al., 2007; Risuen˜o et al., 2005, 2006,
2008). To investigate whether the abTCR and gdTCR share the
same activation principle, we used the best-described ligands
available. First, using the murine G8 gdTCR we show that,
despite T22 tetramer binding and triggering of signaling, the
CD3 CC was not induced. In fact, T22 tetramer and APC stimu-
lation even had the reverse effect in stabilizing the closed CD3
conformation, indicating that the gdTCR structure was sensitive
to T22 binding. Second, the human Vg9Vd2 TCR was activated
by phosphoantigens, but the CD3 CC was not observed,
although we used conditions that allow its detection in the
Figure 6. Induction of the CD3 CC Reduces Anti-CD3-Induced Cytokine Secretion in Vg9Vd2 T Cells
(A) F.CD3εWT, F.CD3εK76T, and F.CD3εC80G cells were stimulated for 7 hr with 3 mg/ml plate-bound 2C11 followed by staining the cells with anti-CD69 and
gating on the GFP+ cells for analysis by flow cytometry (n = 3). The mean ± SD is shown. One-way ANOVA and post hoc Tukey HSD tests were used: ***p < 0.001.
(B) The Vg9Vd2 T cell clone was stimulated in triplicates for 4 (CD69) or 20 (CD25) hr with 5 mg/ml soluble UCHT1 or OKT3 and stained with anti-CD69 or anti-CD25
for flow cytometry (n > 3).
(C) Human freshly isolated, purified gd T cells (gdPBMCs) were stimulated for 20 hr and analyzed as in (B) (n = 1).
(D) The cellular supernatants from (B, 4 hr) were used to measure IFN-g and TNF-a by a multiplexed bead assay (IFN-g n = 2, TNF-a n = 3).
(E) The Vg9Vd2 T cell clone was stimulated with 5 mg/ml plate-bound UCHT1 or OKT3 in triplicates and secreted IFN-g and TNF-awere quantified as above (n = 2).
(F) Expanded primary blood gd T cells were labeled with 1 mM Cell Trace Violet and left unstimulated or stimulated with 5 mg/ml soluble UCHT1 or OKT3 as
indicated. After 4 days, proliferation was determined by flow cytometry (left panel) (n = 3).
In (B)–(E), mean ± SD of triplicates is shown. Significances between UCHT1- and OKT3-stimulated cells were determined by the Student’s t test; ns, not
significant; *p < 0.05; **p < 0.01; ***p < 0.001.abTCR (de la Cruz et al., 2011; Gil et al., 2008). Therefore, the
gdTCRs tested do not undergo the CD3 CC upon engagement
by their ligands, which is in sharp contrast to the abTCR
(Figure S7A).
In neither ab nor gdTCRs was exposure of the PRS influenced
by the presence or absence of Ca2+ ions. This indicates that the
CD3 CC is different from the proposed Ca2+-dependent detach-
ment of the CD3ε cytoplasmic tail from the membrane (Shi et al.,
2013), and most likely it occurs upstream of TCR-induced Ca2+
signaling. Likewise, the absence of the CD3ε basic-rich
sequence, required for membrane binding of the CD3ε tail, did
not influence the CD3 CC (de la Cruz et al., 2011).
What might be the difference between gdTCRs and
abTCRs that precludes the CD3 CC upon antigen stimulation
of the gdTCR? First, a low antigen-gdTCR affinity can be
excluded, because the T22-G8 TCRgd interaction is high affinity
KD z100 nM (Crowley et al., 2000), compared to z10 mM for
typical pMHC-TCRab interactions (Davis et al., 1998). Second,
using chimeric TCRs, we observed that induction of the CD3
CC did not depend on pMHC versus T22 binding, but on the C
regions of the TCRab heterodimer. Thus, it is unlikely that the
differential geometry of the T22-gdTCR interaction compared
to the pMHC-abTCR interaction (Adams et al., 2005; RudolphCet al., 2006) is the cause for the absence of this structural change
in the gdTCR.
The capacity to undergo the CD3 CC (or not) mapped to the C
regions of TCRgd/TCRab. In fact, the constant Ig domains of
TCRgd use different amino acids to associate with CD3 than
do those of the TCRab (Allison et al., 2001), which is in line
with previous data suggesting that TCRab are oriented differ-
ently toward CD3 compared to TCRgd (Van Neerven et al.,
1990). For example, the constant Ig domain of TCRb contains
an FG loop that is thought to directly associate with CD3 (Touma
et al., 2006) and that is not present in TCRgd. The structural
difference might be subtle, because in both TCR types the
CD3 dimers might be located on the same side (Kuhns et al.,
2010). Thus, our data suggest that the arrangement of the
complete TCRgd-CD3-z complex might sterically hinder anti-
gen-induced conversion into the open CD3 conformation. In
contrast to antigens, anti-TCR mAbs can force the gdTCR to
adopt the CD3 open conformation. Thus, it is possible that
some gdTCRs could undergo the CD3 CC upon binding to their
ligand.
Despite the fact that the anti-human CD3 mAbs UCHT1 and
OKT3 recognize overlapping epitopes at CD3ε (Arnett et al.,
2004; Kjer-Nielsen et al., 2004), UCHT1 induced the CD3 CC inell Reports 7, 1704–1715, June 12, 2014 ª2014 The Authors 1711
Figure 7. UCHT1, but Not OKT3, Enhances Vg9Vd2 T Cell-Mediated Tumor Cell Lysis
(A and B) Adherent pancreatic ductal adenocarcinoma Panc89 cells were grown on an E-plate of a Real Time Cell Analyzer. After 24 hr human short-term cultured
Vg9Vd2 T cell lines from healthy donor (HD) 1 (A) or HD2 (B) in medium (orange) or together with the indicated concentrations of the mAbs UCHT1 or OKT3 were
added to the assay. The effector target ratio was 12.5:1. The cell index was determined every 5 min over the course of the experiment and normalized to 1 at the
time point of addition of antibodies and gd T cells as shown by the vertical black thin line. The loss of impedance (corresponding to induction of tumor cell lysis)
after addition of the gd T cells was measured over additional 24 hr. Growth of the tumor cells alone (green) or lysis by detergent (black) are shown as controls.
Results of two representative donors out of seven are shown.
(C) The experiment was performed as in (B), but without adding gd T cells.the gdTCR, whereas OKT3 did not. This was intrinsic to the
gdTCR. In contrast, both mAbs triggered the CD3 CC in the
abTCR. OKT3 therefore resembles the T22 ligand in the murine
system. Thus, mAbs can be useful tools for studying the TCR
but do not always mimic antigen engagement. The gdTCR is
more extensively glycosylated on CD3 compared to the abTCR
(Alarcon et al., 1987; Krangel et al., 1987; Siegers et al., 2007;
Van Neerven et al., 1990). Indeed, we show that desialylation
of gd T cells enabled OKT3 to induce the CD3 CC in the
Vg9Vd2 TCR. This gd-specific CD3 glycosylation was dependent
on the expression of TCRgd and not the cellular background
(Siegers et al., 2007), which correlates with the inability of
OKT3 to induce the CD3 CC in Jk.Vg9Vd2 T cells. CD3 deglyco-
sylation (or deglycosylation of other cell surface proteins) might
also enhance gdTCR clustering, promoting the CD3 CC.
In ab T cells, the CD3 CC was required for abTCR triggering
(Martı´nez-Martı´n et al., 2009; Minguet and Schamel, 2008). We
observed activation of human Vg9Vd2 T cells and murine G8
gd T cells by antigen in the absence of detectable induction of
the CD3 CC (Figure S7A). Furthermore, mutating CD3ε such
that its capacity to undergo the CD3 CC was reduced (Martı´-
nez-Martı´n et al., 2009) did not impair upregulation of the activa-
tion marker CD69 in murine Vg1.1 T cells. Thus, in contrast to
abTCRs, the three different gdTCRs tested did not require the
CD3 CC for several T cell activation readouts. Perhaps the
absence of CD3 CC at the gdTCR is compensated by higher
kinase levels (Laird and Hayes, 2010), expression of different
kinases (Latour et al., 1997; Saint-Ruf et al., 2000), or a higher
capacity to cluster (Jensen et al., 2008). Indeed, gd T cells
have an intrinsically stronger signaling capacity (Haks et al.,
2005; Hayes et al., 2005) and may not need the CD3 CC to
amplify activation signals as ab T cells do.
Artificial induction of the CD3CC in the human Vg9Vd2 TCR by
stimulation with UCHT1 had a strong impact on gd T cell acti-
vation. Compared to OKT3, UCHT1 stimulation enhanced prox-
imal gdTCR-induced signaling events, such as Ca2+ influx and
activation of the PI3K/AKT, Ras/Erk and IkB/NFkB pathways1712 Cell Reports 7, 1704–1715, June 12, 2014 ª2014 The Authors(Figure S7B). Complementing OKT3 with the CD3 CC by T cell
desialylation, anti-k light chain or anti-igG treatment resulted in
augmented proximal signaling, suggesting that the CD3 CC
was the cause for this increased activation. Indeed, Ca2+ influx
was reduced in the CD3 CC-defective mutant murine gdTCRs.
This is in line with ab T cells, in which the CD3 CC is required
for proximal signaling (Martı´nez-Martı´n et al., 2009; Minguet
and Schamel, 2008). Furthermore, the lack of CD3 CC during
gdTCR triggering explains the slow kinetics (in comparison to
those of ab T cells) and weak intensities of proximal signaling
when human Vg9Vd2 T cells were stimulated with phosphoanti-
gens and OKT3 (Beetz et al., 2008; Correia et al., 2009; Lafont
et al., 2001), but not with UCHT1 (Lafont et al., 2001).
In contrast to proximal signaling events, production of the
effector cytokine IFN-g and TNF-a by the Vg9Vd2 cells was
reduced when the CD3 CC was present. It seems likely that
strong proximal signaling supported by the CD3 CC (UCHT1)
activates negative feedback loops, which decreases signaling
at later time points. Indeed, UCHT1 enhanced TCR downregula-
tion compared to OKT3. Thus, the lack of negative feedback
loops upon OKT3 stimulation might explain the heightened
ability of OKT3 to trigger cytokine production. Indeed, gd
T cells are strong cytokine producers (Bonneville et al., 2010;
Chien and Konigshofer, 2007; Vantourout and Hayday, 2013).
Immunotherapy using gd T cells is garnering ever-increasing
interest and has been tested in several early phase clinical trials
for different cancers (Bennouna et al., 2008; Dieli et al., 2007;
Kobayashi et al., 2007; Wilhelm et al., 2003; Xu et al., 2008). gd
T cells may be expanded in vivo (Dieli et al., 2007) or ex vivo
and adoptively transferred (Bennouna et al., 2008; Kobayashi
et al., 2011; Nicol et al., 2011). In fact, allogeneic transplantation
is now being considered a doable option, because gd T cells do
not incite graft-versus-host disease, while offering considerable
graft-versus-malignancy effects (Daniele et al., 2012). One
limiting factor is that patient-derived gd T cells, especially from
those who have received chemotherapy or prior zoledronate
treatment, often undergo suboptimal and highly variable
ex vivo expansion (Kobayashi et al., 2011; Nicol et al., 2011). We
showhere that OKT3 stimulation, which does not induce the CD3
CC at the gdTCR, promotes strong proliferation. Thus, it may be
ideally suited for the expansion of gd T cells andwas used for this
purpose before (Dokouhaki et al., 2010).
Besides cellular expansion strong gd T cell activation might be
also required for therapeutic efficacy (Pennington et al., 2005).
We found that induction of the CD3 CC enhanced the PI3K/Akt
and Ras/Erk pathways that are necessary for the antitumor acti-
vity of Vg9Vd2 T cells (Correia et al., 2009). Thus, UCHT1, which
induces the CD3 CC, strongly enhanced gd T cell-mediated
tumor cell killing, resulting in death of all tumor cells. In sharp
contrast, OKT3 slightly blocked the tumor killing activity of the
Vg9Vd2 T cells in most experiments. This was neither due to
enhanced gd T cell proliferation nor increased IFN-g or TNF-a
production by UCHT1-stimulated cells, because OKT3 triggered
greater proliferation as well as IFN-g and TNF-a production than
UCHT1. UCHT1 and OKT3 also induced similar amounts of
apoptosis in the gd T cells. The conclusion that the CD3 CC
promotes gd T cell cytotoxicity could be confirmed by genetic
means using the CD3CCmutant CD3ε in the tumor-killing assay.
Thus, employing these two mAbs may constitute an ideal
combination in the development of gd T cell immunotherapy
for a variety of cancers. Phosphoantigen stimulation at culture
initiation followed by OKT3 stimulation should ensure generation
of sufficient gd T cell numbers for infusion (Dokouhaki et al.,
2010; Lopez et al., 2000) and UCHT1 stimulation just prior to
infusion would enhance cytotoxicity.
In summary, our study identifies fundamental differences in
gdTCR versus abTCR triggering mechanisms, which have likely
evolved in response to differences in the respective antigens
recognized by these receptors. Our findings, suggesting the
use of UCHT1 or other drugs inducing the CD3 CC in human
gd T cells, may inform the design of novel clinical immunotherapy
protocols.
EXPERIMENTAL PROCEDURES
Cells, Mice, Reagents, and Cloning
This information is given in the Supplemental Information.
Cell Stimulation, Lysis, and Nck-PD Assay
Cells were stimulated for 5 min or the indicated times at 37C or for 30 min on
ice with 5 mg/ml anti-TCR. Cells were lysed at a maximum of 303 106 cells/ml
in 1 ml lysis buffer containing the indicated detergent (0.3% Brij96V or 0.3%
Brij58) as described (Schamel et al., 2005). Fifty microliters were kept as a
lysate control. For the SH3-PD assay, 600 ml were incubated with 3–5 ml gluta-
thione-Sepharose beads bound to the first SH3 domain of Nck for 3 hr at 4C
(Gil et al., 2002). Beads were washed vigorously four times in lysis buffer
containing 0.5% Brij96V. Three hundred microliters of the lysate was used to
confirm antibody binding of the stimulating antibodies by immunoprecipita-
tions using 3 ml protein G- and 3 ml protein A-coupled Sepharose (Amersham
Pharmacia Biotech) as described (Schamel et al., 2005).
T1.4 ab hybridoma cells were incubated with photoreactive H2-Kd-pepABA
monomers or tetramers. Subsequently, cells were UV-irradiated to covalently
crosslink the pMHC to the T1.4 abTCR. Upon lysis, the SH3-PD was per-
formed as above.
For stimulation by APCs, we used splenic B cells from CD3ε knock out
C57BL/6 mice (avoiding contamination by T cells) that were stimulated over-
night with 5 mg/ml LPS, Daudi cells, or Daudi cells pulsed for 4 hr with 2 mM
zoledronate 10 hr before use. T cells were mixed with the APCs at a 1:1 (gdCT cell:Daudi cell) or 1:2 (G8 gd T cell hybridoma:splenic APC) ratio. After stim-
ulation and lysis, the SH3-PD was performed as above. For the unstimulated
cells, T cells and APCs were lysed separately, and the lysates were combined
for the SH3-PD.
Activation Assays
For themeasurementofphosphorylatedErk,Akt, and IkBa, cellswerestimulated
and lysed and a multiplexed bead assay was performed using BioPlex200 sys-
temasper themanufacturer’s instruction (Bio-Rad). To induce TCRdownmodu-
lation or CD69 and CD25 upregulation cells were plated at 2 3 105 per 96-well
plate well and soluble antibodies were added at a concentration of 5 mg/ml.
Cells were incubated at 37C as indicated. Supernatants were kept at 80C,
and the relative amount of IFN-g and TNF-a was measured within 2 weeks on
the BioPlex200 system following themanufacturer’s instruction (Bio-Rad). Alter-
natively, TNF-a was measured using an ELISA kit (BD Biosciences).
Ca2+ Flux and Flow Cytometry
Cells were labeled in the dark with 5 mg/ml of Indo-1 and 0.5 mg/ml of pluronic
F-127 (both Molecular Probes and Life Technologies) for 45 min in RPMI, 1%
fetal calf serum. After 1 min of recording at 37C, cells were stimulated with
5 mg/ml OKT3 or UCHT1 mAb with or without 2.5 mg/ml of the indicated cross-
linking antibody. The change of the ratio of Indo-bound versus Indo-unbound
was followed for 300 s with a LSRII fluorescence spectrometer (BD Biosci-
ences). Data were analyzed with the FlowJo 6.1 software.
Tumor Cell Killing Assay
Adherent pancreatic ductal adenocarcinoma Panc89 cells were added to wells
of anE-plateof aRealTimeCellAnalyzer (Roche) for 24hr. The impedanceof the
tumorcellswasmeasuredover this timeperiod.After 24hr,when the tumorcells
were in the linear growth phase, the indicated concentrations of anti-CD3 mAb
ormedium together with the short-term cultured gd T cell lineswere added. The
loss of impedance after addition of gd T cells was measured over additional
24hr. Asacontrol formaximal lysis, TritonX-100wasadded to thePanc89cells.
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